Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
about
Clinical effectiveness of dolutegravir in the treatment of HIV/AIDSMetagenomics: A New Way to Illustrate the Crosstalk between Infectious Diseases and Host MicrobiomeDolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIVResistance against Integrase Strand Transfer Inhibitors and Relevance to HIV PersistenceCurrent perspectives on HIV-1 antiretroviral drug resistanceGut Microbiota in HIV Infection: Implication for Disease Progression and ManagementApproved Antiviral Drugs over the Past 50 YearsNew Antiretroviral Treatment for HIVMight dolutegravir be part of a functional cure for HIV?Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trialsDolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and reviewDolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kineticsTherapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical TrialsHIV integrase inhibitors: a new era in the treatment of HIV.Dolutegravir: clinical efficacy and role in HIV therapy.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patientsDolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 studySimilar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German 'WIP' cohort.Single-Tablet Regimens in HIV TherapyResistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.Fitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latencyA sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasmaAntiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance ProfileEffects of boceprevir and telaprevir on the pharmacokinetics of dolutegravirEffect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjectsDolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.What if HIV were unable to develop resistance against a new therapeutic agent?Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.The role of dolutegravir in the management of HIV infectionUneven genetic robustness of HIV-1 integrase.Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France.Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter TrialCost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States.Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients.Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada.No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects.
P2860
Q26778450-A00A1FBE-4CF4-4798-B13C-4315484D9426Q26779142-71DFE3D5-3BA0-4534-895C-3EA2886CFE04Q26799712-FCBA5386-D20C-4C9B-A42C-D986AA647D22Q26801286-D2BB1F68-C73C-4189-B19A-D808BD446A18Q26852626-13AEB1C6-1967-427E-8509-C684DC524F19Q27014742-189F7254-A7BE-4BA9-8F19-F50376342CCFQ27755387-B3AB7DF7-DF35-4EAA-9462-953552A3FCAEQ28069829-6F81C755-4434-45CF-93D2-78C9851DEE34Q28071420-11FA9B50-5B00-4C41-B9F1-E57EEF6714D6Q28077053-8571AFF9-A31E-49BE-8E6C-E09B46B8352AQ28086985-46DA6217-789B-498D-8A59-DB30A3CCA923Q28534464-111E7C71-0938-4091-B710-E9DC232B7035Q28553571-03D6454F-7BCB-4503-AC50-966DB04373A2Q30956943-E4FD19E3-43E6-41F2-AB6F-B83DF1FEBA2FQ33725024-D9ABCE00-B0F4-4AD2-BE82-CE4CD5E04023Q33775397-5770F6A2-CA53-4A8B-AE26-D9DB3D51A5CEQ33878754-190EECB0-D647-445C-87C9-B9B90C5DCD47Q33880221-E1C59C0C-A1DC-47F4-A211-0E4B9DAC8F79Q33910849-D327A2C2-E1E9-4F13-B943-5DAB74A094AFQ33939110-496F42C2-E0AA-450E-967C-9AFAA8F8F317Q33963458-931043EB-4260-4784-8381-0AF5FFBCC7CDQ34059119-F39B0D70-7A8D-4014-8F40-AF9FFFB54EA1Q34151623-2C137252-6710-45D2-8149-7816CFF9A632Q34303589-7107A650-3104-47F9-AF8F-ACE003902432Q34496927-26C0049E-BC97-46E6-AA6B-09633CA7FA49Q34540677-76DDDA5C-B8FE-4283-8357-DECDA5448C5CQ34570900-9EA657FF-CA81-4680-A00A-4126886E13EAQ34596882-B7AE67B2-C09C-4A9F-A9B2-52E2D0726A8DQ34726183-C416D201-5526-422F-B5C5-278470F6C745Q35021555-1E639C28-E823-419C-8B50-B06CEB90DA12Q35051393-63CF9478-F2F8-4ABA-8211-66B4568CAEA0Q35103606-C541CDAB-3147-4608-A89A-4334BEE1FDF2Q35121450-0C2B242C-6AED-4F12-BFB4-6A11A6BC69CEQ35360391-C2BF59C6-BCDB-430F-BDDA-0CB1BF9C9E69Q35880715-B2ADA600-807A-4428-B612-213D1103B934Q35885190-46C907F0-C9BB-4352-BB79-5A91CAB2BCABQ35903617-6AFE6B7F-09CE-4090-80F3-3A34D1DD2A19Q36072494-90F9CB19-FDF7-44BC-9A21-3ED2684ED0E0Q36073384-A75A34E3-EB9F-4C19-BE6B-5D651496EE5FQ36083734-F675022B-BE8E-47A1-8988-147136A3E6B0
P2860
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Dolutegravir versus raltegravi ...... non-inferiority SAILING study.
@en
Dolutegravir versus raltegravi ...... non-inferiority SAILING study.
@nl
type
label
Dolutegravir versus raltegravi ...... non-inferiority SAILING study.
@en
Dolutegravir versus raltegravi ...... non-inferiority SAILING study.
@nl
prefLabel
Dolutegravir versus raltegravi ...... non-inferiority SAILING study.
@en
Dolutegravir versus raltegravi ...... non-inferiority SAILING study.
@nl
P2093
P50
P1433
P1476
Dolutegravir versus raltegravi ...... non-inferiority SAILING study.
@en
P2093
Anton L Pozniak
Carlos Beltran Buendia
Catherine B Small
David Dorey
Debbie Hagins
Franco Felizarta
Gary Richmond
Horacio Mingrone
Jaime F Andrade-Villanueva
Jan Fourie
P304
P356
10.1016/S0140-6736(13)61221-0
P407
P577
2013-07-03T00:00:00Z